Back to discover
Disease

Heart Arrest

Late-stage therapeutic developmentEmerging researchRising momentum
10
Publications
15
Clinical trials
2
Related conditions
2025
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Extracorporeal cardiopulmonary resuscitation for refractory cardiac arrest.

Research2025-05-30The Lancet. Respiratory medicine

Evolution of brain injury and neurological dysfunction after cardiac arrest in the rat - A multimodal and comprehensive model.

Research2024-05-21Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism

TRPM2 and CaMKII Signaling Drives Excessive GABAergic Synaptic Inhibition Following Ischemia.

Research2024-05-08The Journal of neuroscience : the official journal of the Society for Neuroscience

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 1 clinical trial with recent milestones.
Major developments
Major clinical milestoneImportant
Primary completion2026-05-20
Clinical Milestones1View
Recently completed 1
Activity timeline1

Clinical trials

11 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
15
All trials
3
Active
5
Late-stage
6
Completed
Late-stage studies
Recently completed

Research activity

10 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20192025
Most influential
Recent publications
Major themes8
  • Heart Arrest6
  • Cardiopulmonary Resuscitation2
  • Alzheimer Disease1
  • Atrial Fibrillation1
  • Brain Ischemia1
  • Calcium-Calmodulin-Dependent Protein Kinase Type 21
  • Drug Overdose1
  • Emergency Medical Services1
Leading journals6
  • Circulation2
  • Anesthesiology1
  • Circulation. Cardiovascular quality and outcomes1
  • European heart journal1
  • International journal of molecular sciences1
  • JAMA1
Leading researchers8
  • Callaway CW2
  • Geocadin RG2
  • Greer DM2
  • Neumar RW2
  • Peberdy MA2
  • Taccone FS2
  • Abella BS1
  • Amin AP1
Affiliations (unnormalised)6
  • University of Colorado School of Medicine2
  • Baylor College of Medicine1
  • Boston Children’s Hospital1
  • Boston Children’s Hospital1
  • Brigham and Women's Hospital1
  • Broad Institute of Harvard and MIT1

Related conditions

2 matches

Diseases frequently studied alongside this one. Number shows shared papers.

Disease profile

A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.

Overview

Heart arrest is the cessation of heartbeat or myocardial contraction. It can be reversed in many cases if treated within a few minutes, restoring normal cardiac rhythm and effective circulation. The literature also treats it as a critical emergency state with important complications, mortality, diagnosis, therapy, and prevention considerations.

Causes

The supplied grounding supports chemically induced heart arrest, including opioid overdose with respiratory depression as a precipitating context. Beyond this, no specific aetiologies are supported by the provided material.

Pathophysiology

Heart arrest reflects failure of the heart to contract effectively, resulting in loss of circulation. The reviewed literature emphasizes downstream physiopathology in the post-arrest state, including the need for critical care management, temperature control, and neurological prognostication in comatose survivors. In refractory cases, extracorporeal cardiopulmonary resuscitation is described as a means to restore circulation and tissue oxygenation when conventional resuscitation fails.

Risk factors

The grounding supports opioid exposure, particularly overdose with agents that produce respiratory depression, as a risk context for cardiac arrest. It also notes that long-acting opioids and opioids with high µ-opioid receptor affinity or slow receptor dissociation kinetics are more resistant to naloxone reversal and therefore relevant to prevention of arrest. Patient age and comorbidities are also identified as contributors to outcome in refractory cardiac arrest.

Current standard of care

Standard management is centered on cardiopulmonary resuscitation and rapid restoration of spontaneous circulation. For refractory cardiac arrest, extracorporeal CPR using venoarterial extracorporeal membrane oxygenation is described as an escalation strategy. Post-arrest care includes critical care management, with temperature control and neurological prognostication among the better-supported modalities; in opioid-related cases, naloxone is the specific reversal agent discussed.

AI-generated summary grounded in MeSH and 3 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Cessation of heart beat or MYOCARDIAL CONTRACTION. If it is treated within a few minutes, heart arrest can be reversed in most cases to normal cardiac rhythm and effective circulation.

Identifiers
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.